Understanding psychotic disorders in children with 22q11.2 deletion syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the early signs of psychotic disorders in children diagnosed with 22q11.2 deletion syndrome, a genetic condition that significantly increases the risk of developing schizophrenia. The research will utilize neuropsychological testing, questionnaires, and experimental tasks to assess social cognitive processes and behavioral changes in affected children. By identifying prodromal signals, the study aims to enhance understanding of the onset of psychotic symptoms in this population. The findings could provide insights into potential early interventions for these children.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of 22q11.2 deletion syndrome or no developmental disease
* Aged from 4 to 13 years old
* French language

Exclusion Criteria:

* Diagnosis of intellectual deficiency according to DSM 5 criteria
* Drug prescribed for somatic condition that could influence cerebral functioning

Where it's running

• Hopital Vinatier
  Lyon, Auvergne-Rhône-Alpes, France Recruiting

Study contacts

• Principal investigator: Marie-Noëlle BABINET — Ch Le Vinatier
• Study coordinator: Caroline DEMILY, MD PH
• Email: caroline.demily@ch-le-vinatier.fr
• Phone: 0450915163

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-invasive fetal cell test to check fetal chromosomal status in early pregnancy

  A large, non-invasive blood test in pregnant people between 10 and 20 weeks looks for fetal cells in the mother's blood to see if the baby has certain chromosomal conditions, comparing results to invasive or postnatal diagnoses.

  Recruiting at 9 sites BillionToOne Inc. · Phoenix, Arizona and 8 other locations · NCT07643896

• Two-week intensive brain-focused therapy program for children with neurodevelopmental and chromosomal conditions

  This program will try a two-week, individualized multimodal neurorehabilitation approach for children about 4–12 years old with neurodevelopmental or chromosomal conditions to see if it improves attention, motor skills, communication, and daily functioning.

  Recruiting Healing Hope International · The Woodlands, Texas · NCT07493096

• Evaluating early spinal changes in children at risk for scoliosis

  This study is trying to see how the spines of adolescent girls at risk for scoliosis and kids with a specific genetic condition change over time using MRI scans, to better understand who might develop scoliosis.

  Recruiting UMC Utrecht · Utrecht · NCT05924347

• Examining genetic factors affecting 22q11.2 deletion syndrome severity

  This study is trying to see if certain genetic differences in people with 22q11.2 deletion syndrome affect how severe their symptoms are.

  Recruiting Albert Einstein College of Medicine · New York, New York · NCT00556530

• Comparing Sertraline and Placebo for Treating Anxiety in Children with Neurodevelopmental Disorders

  This study is testing if the medication sertraline can help reduce anxiety in children and teens aged 8-17 with neurodevelopmental disorders like autism and Fragile X syndrome compared to a placebo.

  Recruiting at 6 sites Phase 2 Holland Bloorview Kids Rehabilitation Hospital · Calgary, Alberta and 6 other locations · NCT06081348

• Improving executive function in young people with 22q11.2 deletion syndrome using brain stimulation

  This study is testing if a type of brain stimulation can help improve memory and thinking skills in children and young adults with 22q11.2 deletion syndrome.

  Recruiting University of Geneva, Switzerland · Geneva, Canton of Geneva · NCT05664412

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.